A citation-based method for searching scientific literature

B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh, D B Rawlins, N C Goodwin, R Mabon, B A Harrison, A Wilson, A Sands, D R Powell. Clin. Pharmacol. Ther. 2012
Times Cited: 137







List of co-cited articles
924 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes.
A Oku, K Ueta, K Arakawa, T Ishihara, M Nawano, Y Kuronuma, M Matsumoto, A Saito, K Tsujihara, M Anai,[...]. Diabetes 1999
142
8

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N. Engl. J. Med. 2013
8

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
Giulia Ferrannini, Thomas Hach, Susanne Crowe, Arjun Sanghvi, Kevin D Hall, Ele Ferrannini. Diabetes Care 2015
136
8

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
619
8

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N. Engl. J. Med. 2016
8

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.
Sanjay K Banerjee, Kenneth R McGaffin, Núria M Pastor-Soler, Ferhaan Ahmad. Cardiovasc. Res. 2009
93
7

Expression of the Na+-D-glucose cotransporter SGLT1 in neurons.
R Poppe, U Karbach, S Gambaryan, H Wiesinger, M Lutzenburg, M Kraemer, O W Witte, H Koepsell. J. Neurochem. 1997
74
9

Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus.
Volker Vallon, Michael Rose, Maria Gerasimova, Joseph Satriano, Kenneth A Platt, Hermann Koepsell, Robyn Cunard, Kumar Sharma, Scott C Thomson, Timo Rieg. Am. J. Physiol. Renal Physiol. 2013
181
7

Regulation of the human Na+-dependent glucose cotransporter hSGLT2.
Chiara Ghezzi, Ernest M Wright. Am. J. Physiol., Cell Physiol. 2012
64
10

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
T Heise, E Seewaldt-Becker, S Macha, S Hantel, S Pinnetti, L Seman, H J Woerle. Diabetes Obes Metab 2013
154
7

Renal Na(+)-glucose cotransporters.
E M Wright. Am. J. Physiol. Renal Physiol. 2001
321
7

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.
Kristina M Johnsson, Agata Ptaszynska, Bridget Schmitz, Jennifer Sugg, Shamik J Parikh, James F List. J. Diabetes Complicat. 2013
118
7





Tofogliflozin: first global approval.
Raewyn M Poole, Jennifer E Prossler. Drugs 2014
39
17

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2012
7


Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N. Engl. J. Med. 2013
7

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
B Komoroski, N Vachharajani, Y Feng, L Li, D Kornhauser, M Pfister. Clin. Pharmacol. Ther. 2009
225
7

Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Nicole C Goodwin, Ross Mabon, Bryce A Harrison, Melanie K Shadoan, Zheng Y Almstead, Yiling Xie, Jason Healy, Lindsey M Buhring, Christopher M DaCosta, Jennifer Bardenhagen,[...]. J. Med. Chem. 2009
32
21



Phosphorylation of RS1 (RSC1A1) Steers Inhibition of Different Exocytotic Pathways for Glucose Transporter SGLT1 and Nucleoside Transporter CNT1, and an RS1-Derived Peptide Inhibits Glucose Absorption.
Maike Veyhl-Wichmann, Alexandra Friedrich, Alexandra Vernaleken, Smriti Singh, Helmut Kipp, Valentin Gorboulev, Thorsten Keller, Chakravarthi Chintalapati, Rüdiger Pipkorn, Marçal Pastor-Anglada,[...]. Mol. Pharmacol. 2016
13
53


Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes.
Nicole C Goodwin, Zhi-Ming Ding, Bryce A Harrison, Eric D Strobel, Angela L Harris, Melinda Smith, Andrea Y Thompson, Wendy Xiong, Faika Mseeh, Debra J Bruce,[...]. J. Med. Chem. 2017
18
38

Effect of canagliflozin on circulating active GLP-1 levels in patients with type 2 diabetes: a randomized trial.
Kohzo Takebayashi, Kenji Hara, Tomoko Terasawa, Rika Naruse, Mariko Suetsugu, Takafumi Tsuchiya, Toshihiko Inukai. Endocr. J. 2017
12
58

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
72
9

Gut hormone PYY(3-36) physiologically inhibits food intake.
Rachel L Batterham, Michael A Cowley, Caroline J Small, Herbert Herzog, Mark A Cohen, Catherine L Dakin, Alison M Wren, Audrey E Brynes, Malcolm J Low, Mohammad A Ghatei,[...]. Nature 2002
6


I. Glucose galactose malabsorption.
E M Wright. Am. J. Physiol. 1998
62
9


Na(+)-D-glucose cotransporter in muscle capillaries increases glucose permeability.
Katrin Elfeber, Frank Stümpel, Valentin Gorboulev, Sabine Mattig, Andreas Deussen, Brigitte Kaissling, Hermann Koepsell. Biochem. Biophys. Res. Commun. 2004
24
25

Glucose sensing in L cells: a primary cell study.
Frank Reimann, Abdella M Habib, Gwen Tolhurst, Helen E Parker, Gareth J Rogers, Fiona M Gribble. Cell Metab. 2008
445
6

Localization of the Na+-D-glucose cotransporter SGLT1 in the blood-brain barrier.
Katrin Elfeber, Alwin Köhler, Michael Lutzenburg, Christina Osswald, Hans-Joachim Galla, Otto W Witte, Hermann Koepsell. Histochem. Cell Biol. 2004
49
12

RS1 (RSC1A1) regulates the exocytotic pathway of Na+-D-glucose cotransporter SGLT1.
Maike Veyhl, Thorsten Keller, Valentin Gorboulev, Alexandra Vernaleken, Hermann Koepsell. Am. J. Physiol. Renal Physiol. 2006
23
26

Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.
Raymond V Oliva, George L Bakris. J Am Soc Hypertens 2014
117
6

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.
William L Baker, Lindsay R Smyth, Daniel M Riche, Emily M Bourret, Kevin W Chamberlin, William B White. J Am Soc Hypertens 2014
217
6


Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice.
Ryuichi Moriya, Takashi Shirakura, Junko Ito, Satoshi Mashiko, Toru Seo. Am. J. Physiol. Endocrinol. Metab. 2009
105
6


SGLT2 inhibitors act from the extracellular surface of the cell membrane.
Chiara Ghezzi, Bruce A Hirayama, Edurne Gorraitz, Donald D F Loo, Yin Liang, Ernest M Wright. Physiol Rep 2014
28
21

SGLT2 inhibitors in the treatment of type 2 diabetes.
Farhad M Hasan, Mazen Alsahli, John E Gerich. Diabetes Res. Clin. Pract. 2014
75
8

Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane.
Joanne Marks, Nicolas J C Carvou, Edward S Debnam, Surjit K Srai, Robert J Unwin. J. Physiol. (Lond.) 2003
94
6

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
Sreeneeranj Kasichayanula, Xiaoni Liu, Frank Lacreta, Steven C Griffen, David W Boulton. Clin Pharmacokinet 2014
97
6

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Clifford J Bailey, Jorge L Gross, Delphine Hennicken, Nayyar Iqbal, Traci A Mansfield, James F List. BMC Med 2013
161
6

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
192
6

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
T Forst, R Guthrie, R Goldenberg, J Yee, U Vijapurkar, G Meininger, P Stein. Diabetes Obes Metab 2014
171
6

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
R R Henry, A V Murray, M H Marmolejo, D Hennicken, A Ptaszynska, J F List. Int. J. Clin. Pract. 2012
184
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.